A paper just published in Clinical Cancer Research has suggested that — at least for one immunotherapeutic agent (“vaccine”) in development for the treatment of advanced prostate cancer — it may be possible to define a subgroup of men who are more likely to respond well to treatment than others. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: antibody, glycan, microarray, PROSTVAC-VF, serum | 4 Comments »
Search for new and
ongoing trials on the
CTAG PCa web site